engleski

Clarythromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis - a pilot study

The aim of this pilot study was to determine the efficacy and tolerability of clarithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis (CT). Fifty-two patients older than 18 years of age with diagnosed chronic Chlamydial prostatitis were enrolled. The presence of CT in expressed prostatic secretion or urine specimen voided immediately after prostatic massage was confirmed by isolation on McCoy cells and Lugol staining. The majority of patients suffered from suprapubic pain in the groin. Twelve patients had no clinical symptoms. According to rectal palpation prostate gland was normal in 35 patients tender and soft in 12 and firm in five patients. Clarithromycin was administered orally 500 mg twice daily for 14 days. Simultaneously the patients' partners received 500 mg orally twice daily for 7 days. Clinical efficacy and tolerability of administered clarithromycin were evaluated 1-7 days and 4-6 weeks after the end of treatment. The eradication of CT was achieved in 30 out of 40 patients while 28 patients were clinically cured. Two patients had nausea and elevated serum transaminases. In asymptomatic patients, the eradication of CT was achieved in 10 of 12 patients who reported no side effects. This pilot study has shown an excellent efficacy and tolerability of clarithromycin in the treatment of patients with chronic Chlamydial prostatitis.

clarythromycin; chronic prostatitis

nije evidentirano